Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Ethosuximide is an anticonvulsant used to treat petit mal seizures. An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.
- Mechanism
- Curator reviewed
Binds to T-type voltage sensitive calcium channels. Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1G gives rise to T-type calcium currents. T-type calcium channels belong to the "low-voltage activated (LVA)" group and are strongly blocked by mibefradil. A particularity of this type of channels is an opening at quite negative potentials and a voltage-dependent inactivation. T-type channels serve pacemaking functions in both central neurons and cardiac nodal cells and support calcium signaling in secretory cells and vascular smooth muscle. They may also be involved in the modulation of firing patterns of neurons which is important for information processing as well as in cell growth processes.
- Primary indication
- For the treatment of petit mal epilepsy.Curator reviewed · 1 structured indication
- Formula / weight
- C7H11NO2 · 141.1677 g/mol (avg)
- First approval
- Canada, 2022 · United States, 1994
- Also known as
- Atysmal · Thilopemal
- Code names
- CI-366 · CN-10,395 · PM-671
- Brand names
- Zarontin
Resolves to
HAPOVYFOVVWLRS-UHFFFAOYSA-NSMILESCCC1(C)CC(=O)NC1=OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Ethosuximide, and which of those have an active Phase 3 trial?